182 related articles for article (PubMed ID: 34675197)
1. Calibration-free NGS quantitation of mutations below 0.01% VAF.
Dai P; Wu LR; Chen SX; Wang MX; Cheng LY; Zhang JX; Hao P; Yao W; Zarka J; Issa GC; Kwong L; Zhang DY
Nat Commun; 2021 Oct; 12(1):6123. PubMed ID: 34675197
[TBL] [Abstract][Full Text] [Related]
2. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
4. Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing.
Song P; Chen SX; Yan YH; Pinto A; Cheng LY; Dai P; Patel AA; Zhang DY
Nat Biomed Eng; 2021 Jul; 5(7):690-701. PubMed ID: 33941896
[TBL] [Abstract][Full Text] [Related]
5. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
Patel SS; Pinkus GS; Ritterhouse LL; Segal JP; Dal Cin P; Restrepo T; Harris MH; Stone RM; Hasserjian RP; Weinberg OK
Am J Hematol; 2019 Aug; 94(8):921-928. PubMed ID: 31148220
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
8. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
Ritterhouse LL; Parilla M; Zhen CJ; Wurst MN; Puranik R; Henderson CM; Joudeh NZ; Hartley MJ; Haridas R; Wanjari P; Furtado LV; Kadri S; Segal JP
Mol Diagn Ther; 2019 Dec; 23(6):791-802. PubMed ID: 31673932
[TBL] [Abstract][Full Text] [Related]
9. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
[TBL] [Abstract][Full Text] [Related]
10. Single-Tube qPCR Detection and Quantitation of Hotspot Mutations Down to 0.01% Variant Allele Fraction.
Zhang K; Rodriguez L; Cheng LY; Wang M; Zhang DY
Anal Chem; 2022 Jan; 94(2):934-943. PubMed ID: 34932306
[TBL] [Abstract][Full Text] [Related]
11. Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).
Vanni I; Casula M; Pastorino L; Manca A; Dalmasso B; Andreotti V; Pisano M; Colombino M; ; Pfeffer U; Tanda ET; Rozzo C; Paliogiannis P; Cossu A; Ghiorzo P; Palmieri G;
Diagn Pathol; 2020 Dec; 15(1):143. PubMed ID: 33317587
[TBL] [Abstract][Full Text] [Related]
12. MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.
Blewett T; Rhoades J; Liu R; Xiong K; Sridhar S; Crnjac A; Cheng J; Lawless AR; Frederick DT; Flaherty KT; Makrigiorgos GM; Adalsteinsson VA
Clin Chem; 2024 Feb; 70(2):434-443. PubMed ID: 38069911
[TBL] [Abstract][Full Text] [Related]
13. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Morita K; Kantarjian HM; Wang F; Yan Y; Bueso-Ramos C; Sasaki K; Issa GC; Wang S; Jorgensen J; Song X; Zhang J; Tippen S; Thornton R; Coyle M; Little L; Gumbs C; Pemmaraju N; Daver N; DiNardo CD; Konopleva M; Andreeff M; Ravandi F; Cortes JE; Kadia T; Jabbour E; Garcia-Manero G; Patel KP; Futreal PA; Takahashi K
J Clin Oncol; 2018 Jun; 36(18):1788-1797. PubMed ID: 29702001
[TBL] [Abstract][Full Text] [Related]
14. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
15. Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing.
Abelson S; Zeng AGX; Nofech-Mozes I; Wang TT; Ng SWK; Minden MD; Pugh TJ; Awadalla P; Shlush LI; Murphy T; Chan SM; Dick JE; Bratman SV
Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33298453
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
Delsing Malmberg E; Johansson Alm S; Nicklasson M; Lazarevic V; Ståhlman S; Samuelsson T; Lenhoff S; Asp J; Ehinger M; Palmqvist L; Brune M; Fogelstrand L
Leuk Lymphoma; 2019 Feb; 60(2):409-417. PubMed ID: 30068244
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
18. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
Short NJ; Patel KP; Albitar M; Franquiz M; Luthra R; Kanagal-Shamanna R; Wang F; Assi R; Montalban-Bravo G; Matthews J; Ma W; Loghavi S; Takahashi K; Issa GC; Kornblau SM; Jabbour E; Garcia-Manero G; Kantarjian HM; Estrov Z; Ravandi F
Blood Adv; 2020 Apr; 4(8):1670-1677. PubMed ID: 32324887
[TBL] [Abstract][Full Text] [Related]
19. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
20. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
